Trump Administration Targets Pharma With New Tariffs and Pricing Deals

The Trump administration has implemented a 100% tariff on imported patented pharmaceutical products and their ingredients, citing national security and the need to strengthen U.S. Supply chains. The policy, announced on April 2, 2026, targets branded medications to reduce reliance on foreign manufacturing and lower drug prices for American consumers.

The action was taken under Section 232 of the Trade Expansion Act of 1962. According to a White House proclamation, a Department of Commerce investigation found that the quantity and circumstances of pharmaceutical imports threaten to impair the national security and economy of the United States.

The administration highlighted a significant vulnerability in the domestic supply chain, noting that as of 2025, approximately 53 percent of patented pharmaceutical products distributed within the U.S. Were produced outside the country. This reliance is viewed as a risk to access for life-saving medications during geopolitical or economic disruptions.

Tariff Structures and Implementation

While the baseline tariff is set at 100%, the administration has established several pathways for pharmaceutical companies to reduce or avoid these levies through specific agreements and trade partnerships.

View this post on Instagram

• Onshoring and Pricing Deals: Companies that enter into both onshoring agreements with the Department of Commerce and Most Favored Nation (MFN) pricing agreements with the Department of Health and Human Services (HHS) will qualify for a 0% tariff through January 20, 2029.
• Onshoring Only: Companies that enter into onshoring agreements with the Department of Commerce without MFN pricing agreements will face a 20% tariff.
• Trade Deal Countries: A 15% tariff applies to pharmaceutical products originating from Japan, Korea, the European Union, and Switzerland and Liechtenstein.
• United Kingdom: A lower tariff rate applies to the U.K., subject to a recently concluded pharmaceutical agreement.

The implementation timeline varies by company size. The tariffs will take effect in 120 days for certain large companies and in 180 days for smaller companies.

Exemptions and Exclusions

Not all medical products are subject to these new levies. Generic pharmaceutical products, biosimilars, and their associated ingredients are not subject to tariffs at this time, though the administration stated this will be reassessed in one year.

Specialty pharmaceutical products are also eligible for exemptions. These include drugs for animal health, orphan drugs, and other specialty products, provided they originate from trade deal countries or meet an urgent public health need.

Impact on Smaller Pharmaceutical Firms

The administration is currently negotiating drug-pricing deals with smaller pharmaceutical companies that were not included in the initial round of agreements with larger drugmakers.

These negotiations offer smaller firms a pathway to pledge lower prices in exchange for avoiding the 100% tariffs or avoiding new pricing policies through Medicare. This strategy mirrors the approach used with larger companies, seeking voluntary and confidential agreements to increase domestic manufacturing and reduce costs.

The exact number of companies currently in talks with the administration remains unclear, and it is not yet determined if or when these parties will reach final agreements.

Policy Objectives

The tariffs represent a strategic effort to rein in the pharmaceutical industry and incentivize the return of manufacturing to the United States. By linking tariff relief to pricing agreements and onshoring, the administration aims to make medications more affordable ahead of the midterm elections.

A senior administration official stated that the goal is to ensure the drug supply is protected, secure and domestic.